Sinovac Biotech is in discussion with regulators in other countries, and the WHO, to launch phase III clinical trials in regions where the novel coronavirus is still spreading rapidly, CEO Yin Weidong said BEIJING : The drugmaker behind one of China’s most promising coronavirus vaccine candidates is in talks to conduct late-stage trials globally as the race for immunization against Covid-19 intensifies.
Beijing-based Sinovac Biotech Ltd. is in discussion with regulators in other countries, and the World Health Organization, to launch phase III clinical trials in regions where the novel coronavirus is still spreading rapidly, CEO Yin Weidong said in an interview Thursday. “To evaluate whether the vaccine can give protection, we need to